Dr. Nix joined Certara in June 2018 as Vice President, Integrated Drug Development. Dr. Nix has nearly 30 years of experience as Chief Science Officer, Head of Research and Development, Senior Director and Director level positions in drug development from major pharmaceutical firms spanning multiple clinical indications including oncology, CNS, inflammation (RA/OA), cardiovascular, pain management, metabolic disease, rare complement disorders and supportive care (antithrombolytics and antiemetics). Specific areas of experience and expertise include IND/NDA enabling GLP toxicology, nonclinical and clinical protocol and study report writing, PK data analysis (including PK/PD modeling), pharmacology and MOA studies, ADME, regulatory support and product strategy planning. Darrell is the President and founder of a drug development consulting firm, DDC, LLC and acting VP of Drug Development for Aquilus Pharmaceuticals (2011 – current) and Chief Science Officer of Recardio Inc. (2014-current). Previously Dr. Nix was the Senior Director of Drug Development of Gloucester Pharmaceuticals from 2008 -2010 culminating in the successful Global registration of ISTODAX® (romidepsin) prior to being acquired by Celgene. From 2004-2007 he headed up drug development at Alantos Pharmaceuticals and was part of the M&A team that lead to the company’s acquisition by Amgen in 2007. Prior to Alantos, from 2000-2004 Dr. Nix was Director, Preclinical Development and later Senor Director of Drug Development at Millennium Pharmaceuticals supporting the commercialization of the first in class boronic acid proteasome inhibitor VELCADE™ during pre-launch and launch following US FDA approval. Dr. Nix was a distinguished member of the U.S. Army’s Medical Corp assigned to the US FDA in the Div. of Clinical Pharmacology at the USUHS in Bethesda. Darrell has a BS in analytical chemistry and completed his graduate studies in Clinical Pharmacology at the Uniformed Services University of the Health Sciences (F. Edward Hebert School of Medicine), Bethesda, MD.